Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
Jianhua Yu, … , Susheela Tridandapani, Michael A. Caligiuri
Jianhua Yu, … , Susheela Tridandapani, Michael A. Caligiuri
Published March 1, 2011
Citation Information: J Clin Invest. 2011;121(4):1456-1470. https://doi.org/10.1172/JCI43242.
View: Text | PDF
Research Article Hematology Article has an altmetric score of 7

NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human

  • Text
  • PDF
Abstract

IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias. However, the mechanisms of action and the identity of the cell subset that undergoes leukemic transformation remain elusive. Here we show that in both mice and humans, NKp46 expression marks a minute population of WT NKT cells with higher activity and potency to become leukemic. Virtually 100% of T-LGL leukemias in IL-15 transgenic mice expressed NKp46, as did a majority of human T-LGL leukemias. The minute NKp46+ NKT population, but not the NKp46– NKT population, was selectively expanded by overexpression of endogenous IL-15. Importantly, IL-15 transgenic NKp46– NKT cells did not become NKp46+ in vivo, suggesting that NKp46+ T-LGL leukemia cells were the malignant counterpart of the minute WT NKp46+ NKT population. Mechanistically, NKp46+ NKT cells possessed higher responsiveness to IL-15 in vitro and in vivo compared with that of their NKp46– NKT counterparts. Furthermore, interruption of IL-15 signaling using a neutralizing antibody could prevent LGL leukemia in IL-15 transgenic mice. Collectively, our data demonstrate that NKp46 identifies a functionally distinct NKT subset in mice and humans that appears to be directly susceptible to leukemic transformation when IL-15 is overexpressed. Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.

Authors

Jianhua Yu, Takeki Mitsui, Min Wei, Hsiaoyin Mao, Jonathan P. Butchar, Mithun Vinod Shah, Jianying Zhang, Anjali Mishra, Christopher Alvarez-Breckenridge, Xingluo Liu, Shujun Liu, Akihiko Yokohama, Rossana Trotta, Guido Marcucci, Don M. Benson Jr., Thomas P. Loughran Jr., Susheela Tridandapani, Michael A. Caligiuri

×

Figure 3

NKp46+ NKT cells are CD4– non-CD1d-restricted NKT-like cells.

Options: View larger image (or click on image) Download as PowerPoint
NKp46+ NKT cells are CD4– non-CD1d-restricted NKT-like cells.
   
(A) Sp...
(A) Splenic cells from WT and IL-15tg mice were stained with NK1.1, CD3, CD4, and NKp46 mAbs. Cells were first gated on NK1.1+CD3+, followed by an assessment of NKp46 and CD4 expression. Percentages of cells are only shown for the top right quadrants. (B) Splenic cells from WT and IL-15tg mice were stained with the mAbs of NK1.1, CD3, NKp46, CD19, and CD1d tetramer loaded with the α-C-galactosylceramine analog PBS-57. NK1.1+CD3+CD19– cells were first gated and then examined for NKp46 and CD1d expression. Percentages of cells positive for CD1d tetramer binding are shown. (C) Splenic cells from CD1d-deficient (CD1d KO) mice were stained with NK1.1, CD3, CD19, NKp46, and CD1d tetramer mAbs. CD19+ cells (data not shown) were first gated out, and the remaining cells were examined for the NK1.1+CD3+ population, followed by gating and an analysis of NKp46 and CD1d expression. Percentages of cells staining positive for all 4 quadrants are shown. (D) Splenic cells from IL-15tg T-LGL leukemia mice were stained with CD3, NKp46, CD19, and CD1d tetramer mAbs. CD19+ cells (data not shown) were first gated out, and the remaining cells were examined for the NKp46+CD3+ population, which was then assessed for CD1d expression. Data are representative of 1 out of at least 3 mice showing similar results. The percentage of cells staining positive in top right quadrant is shown for the right panel.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
Referenced in 1 Wikipedia pages
Highlighted by 1 platforms
71 readers on Mendeley
See more details